Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
Kura Oncology Inc (NASDAQ: KURA) closed the day trading at $10.22 down -2.29% from the previous closing price of $10.46. In other words, the price has decreased by -$2.29 from its previous closing price. On the day, 1.48 million shares were traded. KURA stock price reached its highest trading level at $10.56 during the session, while it also had its lowest trading level at $10.17.
Ratios:
For a better understanding of KURA, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.62 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 10.70. For the most recent quarter (mrq), Quick Ratio is recorded 5.12 and its Current Ratio is at 5.12. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.06.
On October 24, 2024, UBS started tracking the stock assigning a Buy rating and target price of $27.UBS initiated its Buy rating on October 24, 2024, with a $27 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 09 ’25 when Hasnain Faheem sold 10,000 shares for $10.98 per share. The transaction valued at 109,764 led to the insider holds 23,983 shares of the business.
FAHEEM HASNAIN bought 10,000 shares of KURA for $116,400 on Dec 09 ’25. On Nov 14 ’25, another insider, Bair Teresa Brophy, who serves as the Chief Legal Officer of the company, sold 8,804 shares for $11.18 each. As a result, the insider received 98,401 and left with 188,139 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KURA now has a Market Capitalization of 889319104 and an Enterprise Value of 359120032. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.55 while its Price-to-Book (P/B) ratio in mrq is 3.67. Its current Enterprise Value per Revenue stands at 3.452 whereas that against EBITDA is -1.503.
Stock Price History:
The Beta on a monthly basis for KURA is 0.24, which has changed by 0.048621535 over the last 52 weeks, in comparison to a change of 0.13613915 over the same period for the S&P500. Over the past 52 weeks, KURA has reached a high of $12.49, while it has fallen to a 52-week low of $5.41. The 50-Day Moving Average of the stock is -3.09%, while the 200-Day Moving Average is calculated to be 32.42%.
Shares Statistics:
Over the past 3-months, KURA traded about 1.88M shares per day on average, while over the past 10 days, KURA traded about 1422760 shares per day. A total of 87.02M shares are outstanding, with a floating share count of 84.38M. Insiders hold about 3.04% of the company’s shares, while institutions hold 96.08% stake in the company. Shares short for KURA as of 1764288000 were 7990490 with a Short Ratio of 4.25, compared to 1761868800 on 8675680. Therefore, it implies a Short% of Shares Outstanding of 7990490 and a Short% of Float of 9.2.
Earnings Estimates
The company has 9.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.79, with high estimates of -$0.45 and low estimates of -$1.01.
Analysts are recommending an EPS of between -$1.18 and -$3.68 for the fiscal current year, implying an average EPS of -$2.34. EPS for the following year is -$2.27, with 9.0 analysts recommending between -$0.42 and -$3.82.
Revenue Estimates
14 analysts predict $81.55M in revenue for. The current quarter. It ranges from a high estimate of $176.95M to a low estimate of $652.41k. As of. The current estimate, Kura Oncology Inc’s year-ago sales were $53.88MFor the next quarter, 14 analysts are estimating revenue of $87.17M. There is a high estimate of $301.6M for the next quarter, whereas the lowest estimate is $5M.
A total of 14 analysts have provided revenue estimates for KURA’s current fiscal year. The highest revenue estimate was $227.1M, while the lowest revenue estimate was $50.8M, resulting in an average revenue estimate of $130.14M. In the same quarter a year ago, actual revenue was $53.88MBased on 14 analysts’ estimates, the company’s revenue will be $209.3M in the next fiscal year. The high estimate is $451.2M and the low estimate is $14.32M.
